BioSpace News Archive

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical drug discovery and development, today reported financial results for its fourth quarter and fiscal 2023, ended August 31, 2023.

NLS Pharmaceutics Ltd. announced that it has received a written notice from Nasdaq Stock Market LLC indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550, which requires listed companies to maintain a minimum bid price of $1.00 per share.

XORTX Therapeutics Inc. announces that further to its earlier press release, the special meeting of shareholders has been rescheduled to 10:00 a.m. on Friday, October 27, 2023.

Bridge Biotherapeutics (KQ288330) announced that the Independent Data Monitoring Committee (IDMC) recommended the continuation of the Phase 2a trial (NCT05483907) evaluating the efficacy, safety, and tolerability of BBT-877 in patients with idiopathic pulmonary fibrosis (IPF).

egnite, Inc., a leading cardiovascular digital health company, announced today that novel research on mitral regurgitation (MR) was presented by cardiologist Rahul Sharma, MBBS, FRACP, at the Transcatheter Cardiovascular Therapeutics (TCT) conference.

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma Lab” or “the Company”), today announced its results for the third quarter ended September 30, 2023.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the third quarter of 2023 after the market close on Wednesday, November 8, 2023.

ChemDiv is excited to announce the expansion of its Business Development Team with the addition of two seasoned professionals, Peter Dmitriev as Business Development Manager and David Stark as Senior Regional Director of Business Development.